Why the study?
Do diabetes and elevated PAI-1 activity impair reperfusion after thrombolytic therapy in patients with acute myocardial infarction?
Do diabetes and elevated PAI-1 activity impair reperfusion after thrombolytic therapy in patients with acute myocardial infarction?
Diabetic patients have higher baseline PAI-1 activity, which is independently associated with impaired enzymatic reperfusion following thrombolytic therapy for acute myocardial infarction.
Answers are grounded in this paper and cite their sources.
Diabetes-linked PAI-1 elevation may delay reperfusion after thrombolysis; hypothesis-generating for targeted interventions.
OBJECTIVE: To compare the activity of plasminogen activator inhibitor (PAI-1) in diabetic and non-diabetic patients admitted with acute myocardial infarction and to determine whether PAI-1 activity influences reperfusion after thrombolytic therapy. DESIGN: Prospective study of patients admitted with acute myocardial infarction. SETTING: District general hospital. MAIN OUTCOME MEASURES: Reperfusion assessed by time to peak release of creatine kinase-MB isoenzyme. RESULTS: Baseline PAI-1 activity and antigen concentrations were significantly higher in diabetic patients (n = 45) than in non-diabetic patients (n = 110) (24.6 (6.9) v 18.6 (7.9) AU/ml (AU = arbitrary units) (p = 0.0001) and 58.8 (13.1-328.8) v 41.0 (10.9-125.4) ng/ml (p = 0.004). Time to peak release of creatine kinase-MB was calculated in 123 (80%) patients. In 98 who received thrombolytic therapy the median time to peak enzyme release was 15.5 h (7.5-24 h) in diabetic patients (n = 26) and 12 h (5-26 h) in non-diabetic patients (n = 72) (p = 0.005). In those with a time to peak release of < or = 12 h, indicating likely successful reperfusion, PAI-1 activity was 17.5 (7.8) AU/ml compared with 22.8 (7.7) AU/ml in those with a time to peak release of > 12 h (p = 0.001). In multiple regression analysis both diabetes (p = 0.0001) and PAI-1 activity at admission (p = 0.029) were independently related to successful reperfusion. In 13 patients with evidence of reinfarction in hospital PAI-1 activity on day 3 was 26.7 (6.4) AU/ml compared with 21.7 (6.3) AU/ml in those without evidence of reinfarction (p = 0.032). CONCLUSION: Both raised PAI-1 activity on admission and diabetes were associated with a reduced likelihood of enzymatic evidence of reperfusion after thrombolytic therapy. Increased PAI-1 activity on day 3 was associated with an increased risk of reinfarction. Diabetic patients had higher PAI-1 activity on admission. This may partly explain their reduced likelihood of reperfusion.
No takes yet. Share an insight, caveat, or question.
Gray et al. (1993) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: